US2012271037A1PendingUtilityA1
Production and purification of il-29
Est. expiryOct 4, 2025(expired)· nominal 20-yr term from priority
C12P 21/02C07K 14/54
57
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The expression vectors and methods using an E. coli expression system for the large scale production of IL-29 are described. The vectors utilize the IL-29 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli . Also included are methods of producing, purifying and pegylating an IL-29 polypeptide.
Claims
exact text as granted — not AI-modified1 . A method of concentrating IL-29 polypeptide comprising:
(a) providing a solution of purified IL-29 polypeptide; (b) adding the solution of IL-29 polypeptide to a tangential flow filtration plate and frame system comprising one or more a 3-10 kDa molecular weight cut-off membrane; (c) applying a transmembrane pressure of 15-25 psi to the system to ultrafilter the solution to a higher concentration; and (d) filtering the concentrated IL-29 polypeptide through a 0.2 μm membrane.
2 . The method of claim 1 wherein the filtered IL-29 polypeptide is at least 98% pure by sodium dodecyl sulfate polyacrylamide gel analysis and aggregates are less than 0.2% by size exclusion HPLC.
3 . The method of claim 1 wherein the filtered IL-29 polypeptide has an endotoxin level of less than 10 endotoxin units per milligram of IL-29 polypeptide in a Limulus amoebocyte lysate assay based on USP <85>.Join the waitlist — get patent alerts
Track US2012271037A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.